- Home
- FMNB vs KROS Comparison
FMNB vs KROS Comparison
Compare FMNB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMNB
- KROS
- Stock Information
- Founded
- FMNB 1887
- KROS 2015
- Country
- FMNB United States
- KROS United States
- Employees
- FMNB N/A
- KROS N/A
- Industry
- FMNB Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- FMNB Finance
- KROS Health Care
- Exchange
- FMNB Nasdaq
- KROS Nasdaq
- Market Cap
- FMNB 503.3M
- KROS 565.0M
- IPO Year
- FMNB N/A
- KROS 2020
- Fundamental
- Price
- FMNB $13.86
- KROS $13.85
- Analyst Decision
- FMNB Hold
- KROS Buy
- Analyst Count
- FMNB 3
- KROS 13
- Target Price
- FMNB $15.33
- KROS $20.63
- AVG Volume (30 Days)
- FMNB 114.6K
- KROS 481.2K
- Earning Date
- FMNB 07-23-2025
- KROS 08-06-2025
- Dividend Yield
- FMNB 4.90%
- KROS N/A
- EPS Growth
- FMNB N/A
- KROS N/A
- EPS
- FMNB 1.28
- KROS 0.11
- Revenue
- FMNB $166,505,000.00
- KROS $214,713,000.00
- Revenue This Year
- FMNB $19.04
- KROS $5,390.70
- Revenue Next Year
- FMNB $4.36
- KROS N/A
- P/E Ratio
- FMNB $10.85
- KROS $128.03
- Revenue Growth
- FMNB N/A
- KROS 91657.70
- 52 Week Low
- FMNB $11.58
- KROS $9.12
- 52 Week High
- FMNB $16.32
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- FMNB 54.56
- KROS 58.98
- Support Level
- FMNB $13.66
- KROS $14.18
- Resistance Level
- FMNB $14.27
- KROS $14.70
- Average True Range (ATR)
- FMNB 0.33
- KROS 0.42
- MACD
- FMNB -0.04
- KROS 0.09
- Stochastic Oscillator
- FMNB 36.94
- KROS 74.84
About FMNB Farmers National Banc Corp.
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.